(A) Schematic of implantation into FRGN liver injury mouse model in vivo experiments. (NTBC: nitisinone; hALB: human albumin; hAAT: human alpha-1 antitrypsin).
(B) Fibrin-gelled DesLO tissue adhered to the mesentery. Implants indicated by yellow arrows.
(C) Mesentery-implanted DesLO harvested tissue after >4 weeks implanted shows tissue growth and vascularization.
(D) Integration of human and mouse CD31 shown via immunofluorescence staining of paraffin section. (Left) Arrows indicate sites of overlap. (Right) Increased zoom of indicated selection denoted in the left image by a dotted rectangle. Lectin denotes vasculature from both species. Scale bars, full image, 50 µm; zoom 25 µm.
(E) ELISA quantification of human albumin protein in mouse serum shows an increase of human albumin between 2 and 4 weeks post-implantation of DesLO (n = 5) at mesentery site, while detected human albumin decreases over this period in iHEP (n = 7, from 3 lots) and PHH (n = 6, from 3 lots). Sham (n = 5) used as control. ****p < 0.0001 determined by ANOVA with Tukey’s multiple comparison test.
(F) Kaplan Meier survival curve of FRGN mice with and without DesLO subrenal implantations. Log-rank p value = 0.0056 by Mantel-Cox test. Implant n = 9, Sham n = 11.
Data are represented as mean ± SEM for (E).
See also Figure S6.